[fcb5af]: / literature / by_gene / TET2.tsv

Download this file

# pmid doi year title Hugo_Symbol
1 33297669 10.3324/haematol.2020.267294 2022 Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. TET2
2 33579790 10.1136/gutjnl-2020-322935 2022 Oncogenetic landscape of lymphomagenesis in coeliac disease. TET2
3 34494161 10.1007/s00428-021-03186-3 2022 Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin. TET2
4 34840089 10.1016/j.clml.2021.10.015 2022 Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations. TET2
5 34847227 10.1182/bloodadvances.2021004926 2022 Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. TET2
6 34937926 10.1038/s41590-021-01087-w 2022 TET deficiency perturbs mature B cell homeostasis and promotes oncogenesis associated with accumulation of G-quadruplex and R-loop structures. TET2
7 34980830 10.1097/PAS.0000000000001859 2022 Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing. TET2
8 34998786 10.1016/j.clml.2021.12.008 2022 The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia. TET2
9 35021606 10.3324/haematol.2021.280003 2022 Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS. TET2
10 35064935 10.1111/his.14619 2022 Parallel evolution of two distinct lymphoid proliferations in clonal haematopoiesis. TET2
11 35255774 10.1080/15548627.2022.2048432 2022 TET2 regulates osteoclastogenesis by modulating autophagy in OVX-induced bone loss. TET2
12 35256801 10.1038/s41591-022-01708-3 2022 High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. TET2
13 35301414 10.1038/s41379-022-01022-w 2022 Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations. TET2
14 35380239 10.1007/s00277-022-04806-x 2022 The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation. TET2
15 35401516 10.3389/fimmu.2022.842439 2022 Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma. TET2
16 35459873 10.1038/s41375-022-01571-8 2022 Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. TET2
17 35492814 10.1016/j.jaccao.2022.01.098 2022 <i>TET2</i> Clonal Hematopoiesis Is Associated With Anthracycline-Induced Cardiotoxicity in Patients With Lymphoma. TET2
18 35533245 10.1158/2643-3230.BCD-21-0177 2022 Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. TET2
19 35543621 10.1080/10428194.2022.2070913 2022 Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis. TET2
20 35577752 10.1016/j.clml.2022.04.015 2022 Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma. TET2
21 35590059 10.1038/s43018-022-00370-5 2022 Acute lymphoblastic leukemia displays a distinct highly methylated genome. TET2
22 35625998 10.3390/cancers14102392 2022 Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality. TET2
23 35652795 10.1080/10428194.2022.2081323 2022 The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing. TET2
24 35835912 10.1038/s41588-022-01121-z 2022 Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. TET2
25 35846192 10.1002/jha2.354 2022 T-cell lymphoma, B-cell lymphoma, and myelodysplastic syndrome harboring common mutations: Trilineage tumorigenesis from a common founder clone. TET2
26 35895386 10.1111/bjd.21791 2022 Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study. TET2
27 35921527 10.1182/blood.2022015451 2022 Clonal germinal center B cells function as a niche for T-cell lymphoma. TET2
28 35995702 10.1016/j.clml.2022.07.009 2022 Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma. TET2
29 36012614 10.3390/ijms23169349 2022 Angioimmunoblastic T-Cell Lymphoma with Exuberant CD30-Positive Follicular Dendritic Cell Proliferation in a SARS-CoV-2 Patient: The Role of Mutational Analysis to Exclude an Associated Follicular Dendritic Cell Sarcoma. TET2
30 36048893 10.1093/ajcp/aqac104 2022 Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant. TET2
31 36059252 10.1080/10428194.2022.2116932 2022 MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. TET2
32 36066697 10.1007/s10875-022-01361-y 2022 Novel Germline TET2 Mutations in Two Unrelated Patients with Autoimmune Lymphoproliferative Syndrome-Like Phenotype and Hematologic Malignancy. TET2
33 33413063 10.2174/1568009620666210106122750 2021 Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). TET2
34 33431788 10.1038/s41392-020-00437-8 2021 CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. TET2
35 33432228 10.1038/s41590-020-00827-8 2021 Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. TET2
36 33496747 10.1182/bloodadvances.2020003081 2021 Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. TET2
37 33512451 10.1182/blood.2020006721 2021 Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells. TET2
38 33544565 10.1097/PAS.0000000000001658 2021 Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II. TET2
39 33546774 10.1186/s40164-021-00200-x 2021 Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas. TET2
40 33569430 10.21037/atm-20-7574 2021 Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity. TET2
41 33650043 10.1007/s00428-021-03071-z 2021 Clinicopathological characterization of follicular helper T-cell-derived peripheral T-cell lymphoma involving Waldeyer's ring. TET2
42 33708776 10.3389/fmed.2021.584507 2021 Case Report: Refusal of an Veno-Arterial Extracorporeal Membrane Oxygenation Due to Malignant Disease? - An Extremely Rare Form of Cardiac Involvement in Acute Myeloid Leukemia. TET2
43 33711909 10.1080/10428194.2021.1894650 2021 Mutational spectrum of <i>de novo NPM1</i>-mutated acute myeloid leukemia patients older than 75 years. TET2
44 33739791 10.1097/PAS.0000000000001646 2021 Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite Lymphoma Potentially Mimicking Richter Syndrome. TET2
45 33829512 10.1111/his.14378 2021 Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma. TET2
46 33849798 10.1016/j.clml.2021.03.002 2021 Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma: A Meta-analysis: RHOA mutations in AITL. TET2
47 33876209 10.1182/blood.2020010510 2021 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia. TET2
48 33928261 10.1038/s43018-020-00161-w 2021 <i>FYN-TRAF3IP2</i> induces NF-κB signaling-driven peripheral T cell lymphoma. TET2
49 33939500 10.1177/10668969211013402 2021 A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor. TET2
50 33941203 10.1186/s13045-021-01068-4 2021 Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. TET2
51 33951889 10.3324/haematol.2020.271957 2021 MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. TET2
52 33990228 10.1186/s40164-021-00224-3 2021 Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas. TET2
53 34021249 10.1038/s41375-021-01289-z 2021 Thyroid MALT lymphoma: self-harm to gain potential T-cell help. TET2
54 34065087 10.3390/ijms22095013 2021 The Impact of Epigenetic Modifications in Myeloid Malignancies. TET2
55 34078586 10.1016/j.clml.2021.04.014 2021 Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events. TET2
56 34108263 10.1158/1535-7163.MCT-20-0377 2021 Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways. TET2
57 34164626 10.1158/2643-3230.BCD-20-0203 2021 Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients. TET2
58 34230442 10.1097/CCO.0000000000000773 2021 Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment. TET2
59 34258755 10.1111/bjh.17639 2021 Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG). TET2
60 34272731 10.1111/bjh.17708 2021 EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features. TET2
61 34390161 10.1002/pbc.29285 2021 Molecular features of non-anaplastic peripheral T-cell lymphoma in children and adolescents. TET2
62 34413196 10.1073/pnas.2110758118 2021 TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia. TET2
63 34424323 10.1182/bloodadvances.2021004653 2021 B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations. TET2
64 34447369 10.3389/fimmu.2021.671755 2021 Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management. TET2
65 34449978 10.1002/dc.24861 2021 Angioimmunoblastic T-cell lymphoma diagnosed from pleural fluid by integration of morphologic, immunophenotypic, and molecular findings. TET2
66 34570179 10.1182/bloodadvances.2021004668 2021 Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. TET2
67 34581268 10.7554/eLife.66395 2021 Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. TET2
68 34590470 10.52586/4970 2021 Methylation alterations and advance of treatment in lymphoma. TET2
69 34615796 10.11406/rinketsu.62.1367 2021 [Epigenetic abnormalities in non-Hodgkin lymphomas]. TET2
70 34621263 10.3389/fimmu.2021.688493 2021 Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. TET2
71 34899857 10.3389/fgene.2021.768913 2021 Epigenetic Regulation of miR-92a and TET2 and Their Association in Non-Hodgkin Lymphoma. TET2
72 35008340 10.3390/cancers14010176 2021 Recent Advances in the Genetic of MALT Lymphomas. TET2
73 35027991 2021 Update on recurrent mutations in angioimmunoblastic T-cell lymphoma. TET2
74 31028364 10.1038/s41379-019-0279-8 2020 Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. TET2
75 31827242 10.1038/s41375-019-0675-6 2020 Familial myeloid malignancies with germline TET2 mutation. TET2
76 31859368 10.1002/path.5376 2020 Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. TET2
77 31870198 10.1080/10428194.2019.1702179 2020 Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for <i>RHOA</i> G17V mutated subtype. TET2
78 31896782 10.1038/s41375-019-0697-0 2020 The clinical mutatome of core binding factor leukemia. TET2
79 32077355 10.1080/10428194.2020.1728751 2020 Longitudinal clonal architecture of acute myeloid leukemia with <i>NPM1</i> driver insertion, early <i>TET2</i> mutations and secondary e6a2 <i>BCR-ABL1</i> rearrangement. TET2
80 32091281 10.1080/10428194.2020.1723016 2020 Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated <i>RUNX1</i> versus acute myeloid leukemia with myelodysplasia-related changes with mutated <i>RUNX1</i>. TET2
81 32107212 10.1158/0008-5472.CAN-19-2787 2020 Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma. TET2
82 32114498 10.1136/jitc-2019-000104 2020 T-cell lymphoma secondary to checkpoint inhibitor therapy. TET2
83 32127923 10.1177/1758835919900856 2020 Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications. TET2
84 32187361 10.1182/blood.2019003535 2020 Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. TET2
85 32203209 10.1038/s41416-020-0788-8 2020 Decreased vitamin C uptake mediated by SLC2A3 promotes leukaemia progression and impedes TET2 restoration. TET2
86 32239385 10.1007/s11523-020-00710-4 2020 Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib. TET2
87 32271188 10.1097/PAS.0000000000001470 2020 Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group. TET2
88 32397113 10.3390/ijms21093323 2020 Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes. TET2
89 32442302 10.1182/bloodadvances.2020001636 2020 Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. TET2
90 32469082 10.1002/cncr.32866 2020 Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma. TET2
91 32518946 10.1182/blood.2020005844 2020 Germline TET2 loss of function causes childhood immunodeficiency and lymphoma. TET2
92 32598477 10.1182/bloodadvances.2019001350 2020 Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. TET2
93 32853377 10.1182/blood.2020006881 2020 Human TET2 bridges cancer and immunity. TET2
94 32945366 10.3892/ijmm.2020.4686 2020 A comprehensive analysis of RHOA mutation positive and negative angioimmunoblastic T-cell lymphomas by targeted deep sequencing, expression profiling and single cell digital image analysis. TET2
95 33106431 10.1073/pnas.2014308117 2020 A mosaic analysis system with Cre or Tomato expression in the mouse. TET2
96 33160401 10.1186/s13148-020-00962-x 2020 Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. TET2
97 33167720 10.1080/10428194.2020.1779255 2020 Venetoclax induced complete remission in extramedullary relapse of AML co-harboring <i>NPM1</i>, <i>TET2</i>, and <i>NRAS</i> mutations after haploidentical hematopoietic stem cell transplantation. TET2
98 33224395 10.14740/jh760 2020 Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant <i>De Novo</i> Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor. TET2
99 33363958 10.1002/ccr3.3430 2020 Angioimmunoblastic T-cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature review. TET2
100 33376237 10.1038/s41392-020-00331-3 2020 Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. TET2